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Abstract 
Background: Nicotine addiction is a major public health problem and is associated with primary 
glutamatergic dysfunction. We recently showed marked global reductions in metabotropic 
glutamate receptor type 5 (mGluR5) binding in smokers and recent ex-smokers (average 
abstinence duration of 25 weeks). The goal of this study was to examine the role of mGluR5 
down-regulation in nicotine addiction by investigating a group of long-term ex-smokers 
(abstinence greater 1.5 years), and to explore associations between mGluR5 binding and relapse 
in recent ex-smokers.  
Methods: Images of mGluR5 receptor binding were acquired in 14 long-term ex-smokers, using 
PET with [(11)C]ABP688, which binds to an allosteric site with high specificity. 
Results: Long-term ex-smokers and individuals who had never smoked showed no difference in 
mGluR5 binding in any of the brain region examined. Long-term ex-smokers showed 
significantly higher mGluR5 binding compared with recent ex-smokers, most prominently in the 
frontal cortex (42%) and thalamus (57%).  
Conclusions: Our findings suggest that down-regulation of mGluR5 is a pathogenetic mechanism 
underlying nicotine dependence and the high relapse rate in individuals previously exposed to 
nicotine. Therefore, mGluR5 receptor binding appears to be an effective biomarker in smoking 
and a promising target for the discovery of novel medication for nicotine dependence and other 
substance-related disorders.  
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Introduction 
The recidivism rate for nicotine consumption is extraordinarily high. Each year, 40% of 
smokers try to quit but only 3–5% achieve prolonged abstinence for 6–12 months after a given 
quit attempt (1). Although the neurobiological mechanisms underlying relapse are largely 
unknown, there is increasing evidence that molecular and neurochemical adaptations in the 
glutamatergic system play an important role in the recidivism for cocaine and nicotine abuse (2).  
There is strong evidence that the metabotropic glutamate receptor type 5 (mGluR5) has a 
specific role in addiction. In 2001, Chiamulera et al. demonstrated that mGluR5 gene knock-out 
mice do not respond to acute administration of various doses of cocaine and fail to acquire 
intravenous self-administration of cocaine (3). Multiple studies have demonstrated that negative 
allosteric modulators of the mGluR5 receptor, such as 2-methyl-6-(phenylethynyl)pyridine 
(MPEP) and 3-((2-methyl-4-thiazolyl)ethynyl)pyridine (MTEP), reduce the self-administration 
of addictive drugs such as cocaine and nicotine (4-10). In addition, there is direct evidence that 
mGluR5 receptor antagonism attenuates reinstatement to nicotine (6, 7). 
We used positron emission tomography (PET) to measure mGluR5 availability with the 
radiolabeled mGluR5 antagonist 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone-O-11C-
methyl-oxime ([11C]ABP688) (11), which binds with high selectivity to an allosteric site. We 
have previously shown a marked reduction in mGluR5 at that time measured as DVR (VT/VND) 
based on a ratio of cortical uptake and cerebellum uptake at equilibrium in a bolus infusion 
setting (12). We found a strong reduction in gray matter DVR between smokers and non-
smokers (20.6% and between ex-smokers and non-smokers (11.5%). Our finding in smokers has 
recently been replicated by another research group (13). 
To test the association between relapse of nicotine addiction and mGluR5 binding, we 
conducted two follow-up studies. First, we measured mGluR5 binding in subjects with a long 
abstinence duration of 78 to 1144 weeks. Given that these subjects belong to about 3% of ex-
smokers with the ability to abstain for a longer period (1), we expected their mGluR5 binding to 
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be positively associated with abstinence duration. Second, we followed the ex-smokers assessed 
in our previous study over time and tested for an association between relapse and mGluR5 
binding in this subsample. Based on our previous study, we hypothesized that abnormally low 
mGluR5 binding predicts a high risk of relapse. In this paper, we have changed our nomenclature 
to the one by Innis et al. (14). Upon request we do not calculate DVR but BPND which is 
calculated as VT/VND - 1 and therefore we had to recalculate the outcome variables which 
resulted in different % changes compared to our previous publication, while the raw uptake data 
remained the same. 
 
 
Material and Methods 
Subjects 
Participants were recruited using local newspaper advertisements and screened at Zurich 
University hospital. Inclusion criterion for the group of long-term ex-smokers was duration of 
nicotine abstinence of more than 1.5 years, having smoked at least 11 cigarettes per day.  
Exclusion criteria included neurological or medical disorders, pregnancy, breast-feeding, 
history of psychosis, manic episodes, current depressive episodes, substance dependence, and 
autism (based on clinical interview as described below). Subjects were enrolled into the study 
after a full explanation of the study design and procedures and after written consent was 
obtained, which was approved by the local ethics committee (Kantonale Ethikkommission 
Zürich). 
All subjects were assessed using an unstructured clinical interview by a psychiatrist and 
the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition Text Revision. Clinical measures included the Beck Anxiety Inventory (BAI) and 
the Beck Depression Inventory (BDI). Magnetic resonance images were assessed for each 
subject to exclude any structural brain pathology.  
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At the time of the PET scan, an additional clinical evaluation, comprising a physical 
examination, BAI, and BDI, was performed. These scores from the BAI and BDI were used for 
further statistical evaluations. 
Subjects in the recent ex-smoker group were questioned regarding potential relapse over 
the telephone 5–12 months (mean 8.4 ± 2.5) after the scanning session. They were asked if, and 
when they had started smoking again and their daily cigarette consumption. 
 
Positron Emission Tomography 
The description of the PET with [11C]ABP688 can be found in detail in a previous study 
(12). In this article, we changed the outcome variable from previously defined DVR to BPND at 
the equilibrium (14).  In the current study we included a new group of long ex-smokers, with 
whom we used the same bolus/infusion protocol as with the previous study with[11C]ABP688 in 
smokers (12). We have shown previously that the bolus infusion method gives reliable results 
using the cerebellum as reference region (15, 16). 
 
Statistical Analysis  
We used PMOD software (Version 3.0; PMOD Technologies, Zurich, Switzerland 
(www.pmod.com) for all analyses. Uptake images were transformed to a common space, the 
Montreal Neurological Institute template. The same 23 regions of interest (ROI) definitions in 
our previous study were used (except brain stem). These included 2 regions within the cingulate 
gyrus (anterior and posterior), 4 cortical regions (frontal, parietal, temporal, and occipital), 3 
regions in the limbic system (medial orbitofrontal cortex, amygdala, and medial temporal lobe), 
3 in the prosencephalon (caudate, putamen, and thalamus) (12). The same grey matter mask 
created for the previous study was used in this analysis. To test for differences in mGluR5 BPND 
between the groups, we used two sample 2-tailed t-tests. Spearman correlations were used to 
assess the relationship between clinical variables and mGluR5 BPND.  
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 Results 
The clinical characteristics of 14 smokers, 14 age- and gender-matched non-smokers, 14 
recent ex-smokers, and14 long-term ex-smokers are shown in Table 1. Only one to two subjects 
per group had a history of one episode of depression but did not show any sign of depression at 
time of scanning. Age did not differ across the groups (F(3,55) = 2.46, p > 0.05), and there was no 
significant difference in age between male and female subjects overall or within the smoker, 
non-smoker, recent ex-smoker, or long-term ex-smoker groups (F(1,55) = 0.03, p > 0.05). The BDI 
scores across all groups did not differ (F(3,55)=0.55, p>0.6). BAI scores on the day of scanning 
were significantly different across all groups (F(3,55) = 3.2 p < 0.05). Scheffe post hoc tests 
revealed that this significant effect was not due to the comparisons with long-term ex-smokers (p 
> 0.4 in all cases). There was no significant difference in the number of cigarettes smoked per 
day (t26 = 0.05; p > 0.9), number of years smoking (t26 = 0.7; p > 0.4), or age of onset (t26 = 0.02; 
p > 0.9) between recent and long-term ex-smokers. There was no significant difference in 
number of cigarettes smoked per day (t26 = 0.9; p >0.3), number of years smoking (t26 = 0.66; p 
>0.5), or age of onset (t26 = 0.96; p > 0.3) between long-term ex-smokers and smokers. 
We did not see a significant effect of age of smoking onset on mGluR5 BPND in the long-
term ex-smoker group, after correction for multiple comparisons. Testing for an effect of age of 
smoking onset as a covariate in a repeated measures analysis of all smoking groups we did not 
see a significant between subjects effect of this factor (F(1,37)=0.026, p>0.8) nor did we see a 
potential effect of the variable age in this comparison between all groups (F(1,50)=3.27 p>0.05).  
We did perform also a repeated measures analysis (regions) combining all groups and did 
not found a significant between subjects effect of gender on the mGluR5 binding (F(1,53)=0.225 
p>0.6).  In the long-term ex-smoker group, there was no difference in mGluR5 BPND between 
male and female subjects (p > 0.05 for all ROIs), with the exception of the left mediotemporal 
region, which showed an uncorrected significant difference in mGluR5 BPND (p < 0.05). 
Performing a repeated measures analysis (using regions as repeat factor) combining all groups no 
significance between subjects effect of gender on the mGluR5 binding (F(1,53)=0.225 p>0.6) was 
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found. The mean [11C]ABP688 activity did not differ significantly among non-smokers, 
smokers, and ex-smokers (729 ± 71, 765 ± 80, 740 ± 34, and 697 ± 61MBq, respectively). Table 
1 and Figure 1summarize the results of the mGluR5 BPND comparisons across the 4 clinical 
groups in the 23 ROIs examined. Overall, there was a significant regions × group effect (F(66,99) = 
2.214; p < 0.0001). The post hoc comparisons between long-term ex-smokers and all other 
groups revealed that all regions showed a significant difference, after Bonferroni correction, in 
mGluR5 BPND between long-term ex-smokers and smokers, except for right thalamus (p < 0.01). 
Percent differences in [11C]ABP688 uptake ranged from 39% to 68% between all groups. When 
we compared long-term ex-smokers and recent ex-smokers, we found a significant difference, 
before Bonferroni correction, in mGluR5  BPND in all regions, except the parietal cortex. After 
Bonferroni correction, only differences in the bilateral frontal, thalamic, and occipital regions 
remained significant. The highest percentage differences were found in the frontal cortex (left: 
42%), occipital cortex (left: 37%), and thalamus (left: 57%). Comparison between long-term ex-
smokers and healthy controls did not reveal any significant effects, after correction, in any 
region, with up to 17% (Figure 1). 
There was no significant correlation between age and mGluR5 BPND  in any region in 
long-term ex-smokers after Bonferroni correction. However, there was a significant correlation 
in the left medial orbitofrontal region, before correction (r = 0.56, p < 0.05).  Performing a 
repeated measures analysis (using regions as repeat factor) combining all groups with age as 
covariate no significance between subjects effect of age on the mGluR5 binding (F(1,50)=3.271 
p>0.07) was found. Group effects remained significant (F(3,50)=20.185 p<0.001). No significant 
correlation, after correction, was observed between mGluR5 BPND and daily consumption of 
cigarettes, years of consumption, abstinence duration, BDI or BAI scores in any regions in long-
term ex-smokers.  
Figure 2 shows the results of our analysis of the follow-up information from the recent 
ex-smoker group. Four recent ex-smokers stayed completely abstinent and another three started 
smoking only 1–2 cigarettes per day (below the WHO criteria for nicotine addiction). Seven 
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recent ex-smokers started smoking again with more than 11 cigarettes per day (or 8 nicotine 
chewing gums). Abstinence duration in the relapsing subgroup was 3–69 weeks (mean = 22 ± 
23.1 weeks) after the scan visit. Abstinence duration did not correlate with mGluR5 BPND in any 
region.  
Discussion 
In a recently published study, we provided the first human evidence of a potential role for 
mGluR5 in nicotine addiction and possibly other substance use disorders. We found marked 
global reductions in mGluR5 binding in smokers and recent ex-smokers with average nicotine-
abstinence duration of 25 weeks compared to controls who had never smoked. This reduction 
occurred in all brain regions, except the brain stem. Current nicotine consumption and estimates 
of current nicotine dependence were not associated with mGluR5 binding. There was no gender 
difference in mGluR5 binding in smokers and recent ex-smokers, whereas female non-smokers 
had significantly lower mGluR5 binding than male non-smokers. In smokers, both age and age at 
smoking onset were positively correlated with mGluR5 binding. 
We could only speculate about the mechanisms underlying the widespread decrease in 
[11C]ABP688 binding to mGluR5 in smokers and recent ex-smokers. The finding may have 
represented a biological trait associated with an increased risk for nicotine dependence, possibly 
due to genetic factors. Alternatively, reduced mGlu5 receptor binding may have been the result 
of mGluR5 down-regulation, possibly because of the nicotine-induced increase in glutamate 
activity (17, 18). Reductions in mGluR5 binding seen in the recent ex-smokers may reflect an 
incomplete recovery of the mGluR5 receptors, given that the recent ex-smokers were abstinent 
for only 25 weeks on average. This supports the hypothesis of a lasting effect of regular nicotine 
consumption, which is possibly associated with the risk of relapse.  
In the first follow-up study, we examined a new group of ex-smokers with average 
abstinence duration of 9 years. These subjects belonged to 1–3% of ex-smokers with the ability 
to abstain for longer periods, giving us the opportunity to investigate mGluR5 binding with 
respect to long-term abstinence. Our findings clearly show that mGluR5 binding across all 
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regions did not differ between the long-term abstinence group and the group of individuals who 
had never smoked. The long-term ex-smoker group showed significantly higher mGluR5 binding 
than the short-term ex-smoker group. This result supports the hypothesis that reduced mGluR5 
binding either is a biological risk factor for nicotine dependence or reflects the amount of 
nicotine-induced glutamate hyperactivity in smokers. It is also consistent with the hypothesis that 
reduced mGluR5 binding in short-term ex-smokers represents an incomplete recovery of 
mGluR5 receptors, lasting for at least the first months of nicotine abstinence. In contrast, the 
results of the first follow-up analysis here argue against the alternative hypothesis that mGluR5 
down-regulation is an effective compensatory change necessary for long-term abstinence. There 
is no gender difference in mGluR5 binding in long-term ex-smokers when compared with 
smokers and recent ex-smokers, whereas women in the control group showed lower mGluR5 
binding than men. This suggests that mGluR5 was down regulated in long-term ex-smokers but 
normalized after extended periods of abstinence. 
Independent of this strong whole brain differences between smoker, recent and long-term 
ex-smoker we looked also into regional differences a posteriori. The contrast between recent and 
long-term ex-smoker should reveal differences between early phases of abstinence and 
successful conquering smoking addiction. We see highest percentage reduction in recent versus 
long-term ex-smokers in the thalamus and frontal cortex. The thalamus is known for high 
densities of nicotinic receptor concentration with strong connection with the frontal cortex (16). 
The “normalization” of these regions seems to be delayed or over proportionally reduced in the 
short-term ex-smoker (from which many did relapse). In order to further analyze network related 
effects more subjects per group would be needed.  
Looking at the differences between long-term ex-smoker and currently smoking subjects 
we see an overall effect of higher binding in the long-term ex-smoker group. Nevertheless, the 
regional analysis revealed the highest difference in percentage is found in mOFC. This is in line 
with various publications on addiction and reward processes. In a recent meta-analysis of studies 
of nicotine dependence and its treatment the authors have extracted that medial and lateral 
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orbitofrontal cortex aside of cingulate, striatum as well as amygdala and thalamus are heavily 
involved in maintenance of smoking and nicotine withdrawal (19). 
The goal of the second follow-up analysis was to explore associations between mGluR5 
binding and relapse in the 14 recent ex-smokers who were included in our previous report (12). 
There were seven ex-smokers who did not smoke at the time of follow-up or smoked only 1 or 2 
cigarettes daily, their mGluR5 binding was not significantly higher than that for individuals who 
relapsed. However, a trend was seen (average 0.55 BPND nonrelapsing vs. 0.47 BPND relapsing, 
p>0.2) for lower mGluR5 binding predicting relapse. This trend needs further investigation in a 
larger sample. This finding is inconclusive since the small sample size does not allow for a 
definitive interpretation for or against a relationship between mGluR5 binding and risk of 
relapse.  
Preclinical studies have found that the functional up-regulation of mGluR2/3 and down-
regulation of mGluR5 are likely to be factors in the transition from drug use to drug dependence 
(20). Specifically, mGluR1/5 and its intracellular binding protein Homer1 were down regulated 
in the nucleus accumbens after withdrawal from chronic cocaine administration (21-24), and the 
drug-induced adaptation of mGluR5 has been implicated in brain reward deficits and somatic 
signs associated with nicotine withdrawal (25). Although these findings consistently suggest that 
mGluR5 plays an important role in the development of substance dependence, the functional role 
of mGluR5 down-regulation remains unclear. It has been suggested that mGluR5 down-
regulation represents a compensatory neuroadaptation (26), diminishing drug-induced reward 
acquisition (27), and reducing the effects of contextual cues in the conditioned behavioral 
responses to nicotine (28). The findings of this study argue against the compensatory 
neuroadaptation hypothesis and favor hypotheses that regard mGluR5 down-regulation as an 
element in the pathogenesis of drug dependence and/or a factor underlying the high rate of 
relapse in nicotine and stimulant consumption.   
Several methodological limitations merit comment. Firstly, the design of this study with 
no repeated assessments of mGluR5 binding cannot conclusively distinguish whether 
12 Funda Akkus 
 
abnormalities in mGluR5 receptor binding reflect a biological vulnerability for nicotine 
dependence or are a consequence of nicotine intake. Secondly, undetected psychiatric or 
neurological conditions may have confounded the results of this study. However, the exclusion 
of subjects with a history of psychiatric disorders did not alter the results. Finally, we used a 
bolus-infusion technique and normalized PET images to the cerebellar radioactivity 
concentration to avoid the need for potentially painful arterial cannulation. This reference tissue 
method was based on the assumption that mGluR5 levels are extremely low in the cerebellum 
relative to the predefined ROIs in other brain areas (29). This assumption is supported by various 
types of evidence, including previous PET studies (30), in vitro and in vivo studies on ABP688 
binding in the cerebellum (29, 31), a postmortem study on cerebellar mGluR5 protein expression 
(32), and studies on cerebellar mRNA expression (33-35).  
In conclusion, we showed that there is normal mGluR5 binding (as compared to healthy 
non-smokers) in ex-smokers who have stayed abstinent for more than a year. These individuals 
represent the 1–3% of smokers who have the ability to stay abstinent over long periods. This 
result suggests that normal mGluR5 binding reflects the relative insensitivity of the glutamate 
system to prolonged nicotine consumption or the full recovery of mGluR5 during nicotine 
abstinence. These findings suggest that down-regulation of mGluR5 in smokers is a pathogenetic 
mechanism underlying nicotine dependence and the high relapse rate in individuals who have 
been previously exposed to nicotine. Therefore, mGluR5 receptor binding appears to be an 
effective biomarker in smoking and a good target for the discovery of novel medication for 
treatment of nicotine dependence and other substance-related disorders.  
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Figures and Table Legends 
 
Figure 1. mGluR5 BPND across all groups  
The bars represent mean (±SD) of mGluR5 BPND) values in selected brain regions: anterior 
cingulate cortex (ACC), mediotemporal cortex (MTL), and medial orbitofrontal cortex (mOFC) 
(mean for left and right sides). Significant differences in all these regions were observed between 
the long-term ex-smoker, recent ex-smoker, and smoker groups. There was no significant 
difference in mGlu5R values between the long-term ex-smoker and healthy control group. 
Statistical details are described in the results section. 
 
Figure 2. Follow-up of recent ex-smokers assessing relapse in relation to grey matter 
uptake 
This figure shows the follow-up of recent ex-smokers in relation to relapse rate. Seven recent ex-
smokers are still abstinent; 4 did not smoke at all and 3 smoked 1 or 2 cigarettes per day. Seven 
participants relapsed to smoking more than 11 cigarettes per day. Comparing regional uptake 
between the groups did not reveal any significant (with and without correction) effects. 
However, there was a tendency for smaller baseline values in (p>0.2) the relapsed subjects. Bars 
represent mean ± SD. Cig./day = number of cigarettes per day. 
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Table 1. Clinical characteristics of study groups  
Clinical characteristic Non-smokers 
(n = 14) 
Smokers (n = 
14) 
Recent ex-
smokers (n = 
14) 
Long-term ex-
smokers (n = 
14) 
Gender (f/m)  8/6 8/6 6/8 
 
6/8 
Age (years) 36.8 (9.6)  36.1 (10.2) 37.7 (10.1) 37.8 (10.1) 
Age of smoking onset 
(years) 
-- 
 
20.4 (5.9) 18.4 (5.3) 18.0 (5.0) 
Number of cigarettes 
smoked per day 
-- 17.0 (4.5) 17.9 (6.0) 19.6 (8.2) 
Number of years 
smoking 
-- 16.8 (7.6) 19.6 (8.8) 
 
19.6 (7.7) 
Duration of nicotine 
abstinence (weeks) 
-- -- 25.0 (19.4) 
 
473.6 (336.1)  
Fagerstrom test for 
nicotine dependence 
(FTND) score 
-- 4.5 (2.0) -- -- 
Beck Anxiety 
Inventory (BAI) score 
1.5 (1.2) 4.3 (4.3) 4.6 (3.3) 2.8 (2.5) 
Beck Depression 
Inventory (BDI) score 
1.8 (2.1) 2.7 (2.6) 2.6 (2.0) 2.4 (2.0) 
Past psychiatric 
history (n) 
 
Alcohol abuse 
 
 
 
1 
 
 
 
1 
 
 
 
0 
 
 
 
0 
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Major depression 
 
Anorexia nervosa 
 
1 
 
0 
 
2 
 
1 
 
 
1 
 
0 
 
 
2 
 
0 
Highest educational 
qualification (n) 
 
High school, 
completed 
 
College, completed 
 
Academic completed,  
 
 
 
 
0 
 
13 
 
1 
 
 
 
 
2  
 
12 
 
0 
 
 
 
 
4 
 
10 
 
0 
 
 
 
2 
 
9 
 
3 
The data is displayed as mean (SD), unless indicated otherwise. 
n refers to the number of participants within this category. The new information from the long ex-smokers is displayed together with the 
information of the other groups, which were already described in our previous study (12).  
 
 
  
19 Funda Akkus 
 
Table 2 
Regions of 
interest 
Long 
ex-
smoker
Non 
smoker 
Recent 
ex-
smoker
Smoker Regions of interest 
Long 
ex-
smoker 
Non 
smoker
Recent 
ex-
smoker
Smoker
  p is cacluated vs. Long-term ex-smoker   p is cacluated vs. Long-term ex-smoker 
Gray matter Occipital left 
 P value 0.826 0.003 0.000  P value 0.669 0.002 0.000
 padjusted 18.999 0.072 0.000  padjusted 15.394 0.014 0.000
BPND 0.688 0.701 0.516 0.383 BPND 0.568 0.586 0.386 0.290
ACC Occiptal right 
 P value 0.743 0.015 0.000  P value 0.548 0.000 0.000
 padjusted 17.100 0.334 0.000  padjusted 12.602 0.007 0.000
BPND 0.964 0.992 0.762 0.574 BPND 0.613 0.580 0.403 0.314
Amgdala left Parietal left 
 P value 0.693 0.012 0.000  P value 0.564 0.106 0.000
 padjusted 15.934 0.268 0.003  padjusted 12.974 2.431 0.003
BPND 0.851 0.887 0.619 0.462 BPND 0.525 0.560 0.423 0.276
Amygdala 
right   Parietal right   
 P value 0.417 0.020 0.000  P value 0.268 0.091 0.000
 padjusted 9.597 0.466 0.005  padjusted 6.155 2.098 0.003
BPND 0.802 0.869 0.606 0.462 BPND 0.551 0.616 0.452 0.297
Caudatus left PCC 
 P value 0.247 0.003 0.000  P value 0.572 0.020 0.000
 padjusted 5.687 0.075 0.000  padjusted 13.157 0.463 0.000
BPND 0.779 0.867 0.556 0.409 BPND 0.837 0.873 0.691 0.504
Caudatus right Putamen left 
 P value 0.550 0.005 0.000  P value 0.905 0.005 0.000
 padjusted 12.657 0.104 0.000  padjusted 20.826 0.125 0.000
BPND 0.783 0.832 0.566 0.417 BPND 0.776 0.769 0.581 0.450
Frontal left Putamen right 
 P value 0.875 0.000 0.000  P value 0.818 0.007 0.000
 padjusted 20.118 0.007 0.000  padjusted 18.820 0.168 0.001
BPND 0.745 0.757 0.484 0.370 BPND 0.758 0.772 0.557 0.435
Frontal right Temporal left 
 P value 0.507 0.002 0.000  P value 0.546 0.003 0.000
 padjusted 11.651 0.042 0.000  padjusted 12.563 0.064 0.000
BPND 0.727 0.774 0.508 0.380 BPND 0.807 0.765 0.593 0.418
Medial 
temporal left   Temporal right   
 P value 0.844 0.009 0.000  P value 0.609 0.003 0.000
 padjusted 19.416 0.216 0.000  padjusted 14.015 0.062 0.000
BPND 0.77 0.755 0.572 0.401 BPND 0.786 0.754 0.596 0.415
Medial 
temporal right   Thalamus left   
 P value 0.825 0.589 0.001  P value 0.164 0.001 0.001
 padjusted 18.983 0.589 0.001  padjusted 3.777 0.021 0.033
BPND 0.579 0.724 0.550 0.380 BPND 0.481 0.572 0.021 0.033
mOFC left   
Thalamus 
right   
 P value 0.783 0.015 0.000  P value 0.187 0.001 0.003
 padjusted 18.000 0.356 0.002  padjusted 4.291 0.023 0.080
BPND 0.605 0.633 0.412 0.196 BPND 0.513 0.606 0.276 0.313
mOFC right 
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 P value 0.599 0.006 0.000
 padjusted 13.786 0.147 0.001
BPND 0.579 0.629 0.386 0.202
 
  
 
 
 
